Haemonetics

Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, Hospital, and Corporate. The Plasma segment offers automated plasma collection and donor management software systems. The Blood Center segment provides solutions for donor collection centers' ability to acquire blood, filter blood, and separate blood components. The Hospital segment includes hemostasis management, cell salvage, and transfusion management services that help decision makers in hospitals optimize blood acquisition, storage, and usage in critical settings. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Boston, MA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Haemonetics reports robust Q1 earnings, eyes U.S. growth amid challenges

Haemonetics delivered strong financial performance in Q1 fiscal 2023, driven by robust revenue growth in both the Plasma and Hospital segments. The company's focus on the U.S. market and plans for accelerating growth indicate a positive outlook. However, challenges related to potential cuts in donor payments and varying market conditions outside the U.S. require careful navigation.

Haemonetics Corporation reports robust Q1 fiscal 2024 performance and eyes international expansion

Haemonetics Corporation delivered impressive Q1 fiscal 2024 results, driven by strong revenue growth and improved operating income. The company faces challenges in managing inventory replenishment and potential competition in the autoimmune space. However, opportunities lie in leveraging its robust product portfolio and expanding into international markets.

Haemonetics reports strong Q3 performance, eyes European expansion for growth

Haemonetics delivered robust financial results in Q3, driven by strong revenue growth and strategic initiatives. While facing challenges related to staffing and donor issues, the company is well-positioned to leverage opportunities in expanding markets and technological advancements to drive future growth.

Haemonetics posts robust earnings, eyes global expansion for growth

Haemonetics delivered strong financial results in Q4 2023 and fiscal '23, driven by robust revenue growth and improved earnings per share.
The company's focus on key segments like Plasma, Hospital, Hemostasis, and Vascular Closure positions it well for future growth and market expansion.
While facing challenges such as cost pressures and competitive landscapes, Haemonetics remains optimistic about its ability to drive profitability and market share.
Strategic initiatives, including a modest ramp in market resources and international expansion, present opportunities for Haemonetics to capitalize on market demand and enhance shareholder value.

Haemonetics excels in Q1 '24, eyes growth amid challenges

Haemonetics delivered robust financial performance in Q1 '24, with significant revenue growth and margin expansion.
While facing challenges like product recalls, the company remains focused on value creation and growth acceleration strategies.
Opportunities for growth exist through market scaling, product innovations, and leveraging trial implications for demand growth.

Haemonetics posts robust Q2 earnings, eyes U.S. and international growth

Haemonetics reported strong Q2 results with increased earnings and revenue growth. The company's strategic acquisitions and focus on innovation position it well for future expansion. Challenges in the Blood Center segment require attention, but overall, Haemonetics is poised for continued growth.

Haemonetics posts robust Q3 earnings, eyes growth through innovation

Haemonetics delivered strong financial performance in Q3 2024, driven by revenue growth and operational efficiency improvements.
The company's focus on innovation, technology enhancements, and strategic acquisitions positions it well for future growth and market leadership.
While facing challenges in certain revenue segments, Haemonetics remains poised to capitalize on opportunities for expansion and margin improvement.

Haemonetics posts robust Q4 results, eyes growth through acquisitions

Haemonetics' Q4 2024 performance reflects strong revenue growth and profitability, driven by successful product launches and acquisitions.
While the company faces challenges in margin targets and integration post-acquisitions, strategic focus on innovation and market expansion presents growth opportunities.
Emphasis on non-GAAP measures and regulatory clearances underscores Haemonetics' commitment to transparency and product quality.
Fiscal year 2025 guidance signals a positive outlook for revenue growth and operational efficiency, positioning the company for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, and Hospital. The Plasma segment offers automated plasma collection and donor management software systems. The Blood Center segment provides solutions for donor collection centers' ability to acquire blood, filter blood, and separate blood components. The Hospital segment includes hemostasis management, cell salvage, and transfusion management services that help decision makers in hospitals optimize blood acquisition, storage, and usage in critical settings. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Boston, MA.

BOSTON, June 3, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient outcomes, today announced that it has entered into a definitive agreement to sell its Fajardo, Puerto...

Haemonetics Announces Blood Filter Supply Agreement And Sale Of Puerto Rico-Based Manufacturing Operations To GVS, S.p.A

Boston Scientific

Boston Scientific, best known for its products in interventional medical specialties, has seen its stock price grow roughly 50% in the last few years. In comparison, Haemonetics, one of the world’s largest blood management companies, has seen its stock grow by a stellar 90% during the same period.

Should You Pick Boston Scientific Over Haemonetics?

BOSTON, May 28, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient outcomes, today announced that it has entered into a definitive agreement to sell certain blood donor...

Haemonetics Announces Sale Of U.S. Blood Donor Management Software Solution Assets To The GPI Group

Haemonetics's (HAE) CEO Chris Simon on Q4 2020 Results - Earnings Call Transcript

Haemonetics' (HAE) fourth-quarter fiscal 2020 results reflect strong performance by Plasma segment despite dismal overall performance during the coronavirus-led crisis.

Haemonetics (HAE) Q4 Earnings Lag Estimates, Margins Expand

Haemonetics (HAE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Haemonetics (HAE)

DexCom

Perrigo

Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.

3 Medical Product Stocks Set to Beat This Earnings Season: DXCM, HAE & PRGO

Haemonetics (HAE) expands its portfolio with the buyout of enicor. With the latter's whole blood coagulation testing system, the company will address a wider range of criticalities in medicine.

Haemonetics (HAE) Buys enicor to Expand Testing Portfolio

Haemonetics (HAE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Haemonetics (HAE) Upgraded to Buy: Here's What You Should Know

Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock?

Why Is Haemonetics (HAE) Down 8.4% Since Last Earnings Report?

Haemonetics (HAE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Haemonetics (HAE): Strong Industry, Solid Earnings Estimate Revisions

Haemonetics (HAE) witnesses high investor confidence on solid prospects.

Here's Why You Should Retain Haemonetics in Your Portfolio Now

Is  (HAE) Outperforming Other Medical Stocks This Year?

Has Haemonetics (HAE) Outpaced Other Medical Stocks This Year?

Haemonetics (HAE) fiscal third-quarter 2020 results reflect strong performances in Plasma and Hospital segments.

Haemonetics (HAE) Q3 Earnings & Revenues Beat, Margins Expand

Haemonetics Corporation (HAE) CEO Christopher Simon on Q3 2020 Results - Earnings Call Transcript

Haemonetics (HAE) delivered earnings and revenue surprises of 23.68% and 2.29%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Haemonetics (HAE) Q3 Earnings and Revenues Beat Estimates

Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Haemonetics (HAE) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

NuVasive

NUVA vs. HAE: Which Stock Is the Better Value Option?

NUVA vs. HAE: Which Stock Should Value Investors Buy Now?

Haemonetics (HAE) expands the transfusion management portfolio with SafeTrace Tx, the latest in its transfusion management software product line.

Haemonetics (HAE) Launches SafeTrace Tx in North America

Why Is Haemonetics (HAE) Down 0.1% Since Last Earnings Report?

Guidewire Software

Hermes International

To increase the odds of unearthing high-quality companies, Benjamin Graham, the father of value investing, recommended investors look for stocks with a current ratio of more than two and a higher working capital than long-term debt.

3 Quality Companies for the Value Investor's Portfolio

The global commercial availability of the cartridge is likely to bolster Haemonetics' (HAE) TEG portfolio.

Haemonetics Launches TEG 6s PlateletMapping Assay Cartridge

Haemonetics (HAE) witnesses a steady uptick in Plasma franchise, fueled by favorable price, volume and mix.

Haemonetics (HAE) Grows on New Products, Robust Plasma Sales

Haemonetics (HAE) delivers robust fiscal second-quarter revenues, fueled by strong performances in Plasma and Hospital segments.

Haemonetics (HAE) Beats on Q2 Earnings, Raises '20 EPS View

Haemonetics' (HAE) CEO Chris Simon on Q2 2020 Results - Earnings Call Transcript

News for Haemonetics Stock (HAE)